ABT-530

February 2, 2016May 20, 2016

AbbVie’s Six Hepatitis C Clinical Trials Now Enrolling Patients

News

AbbVie has announced it will initiate six global Phase 3 clinical studies to evaluate the safety and efficacy of two drug candidates: ABT-530, an NS5A inhibitor, and ABT-493, an NS3/4A protease inhibitor, ... Read more

November 19, 2015November 19, 2015

AbbVie’s Chronic Hepatitis C Treatments Working Well in Trials

News

AbbVie recently announced encouraging results from the SURVEYOR clinical trials of its investigational HCV drug regimen, ABT-493 and ABT-530, in non-cirrhotic patients who are positive for chronic hepatitis C virus (HCV) infection. Specifically, ABT-493, an inhibitor of the NS3/4A protease, ... Read more